Compare TROX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROX | CMPS |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.2M | 732.6M |
| IPO Year | 2012 | 2020 |
| Metric | TROX | CMPS |
|---|---|---|
| Price | $6.98 | $6.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $5.93 | ★ $27.14 |
| AVG Volume (30 Days) | ★ 4.3M | 4.0M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ 0.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,898,000,000.00 | N/A |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $4.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $2.25 |
| 52 Week High | $8.80 | $8.90 |
| Indicator | TROX | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 48.57 |
| Support Level | $4.98 | $5.95 |
| Resistance Level | $8.80 | $7.02 |
| Average True Range (ATR) | 0.62 | 0.61 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 21.07 | 37.86 |
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.